Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial
Andrew W Hitchings,Dilys Lai,Paul W Jones,Emma H Baker,Metformin in COPD Trial Team,Srikanth Akunuri,Michael Tumilty,Jan Poloniecki,Anjali Balasanthiran,Cielito Caneja,Kylie Norrie,Theresa Weldring,Jaime Carungcong,Richard Harrison,Nicola Bateman,June Battram,Sam Kemp,Karen Whysall,Mark Wilkinson,Jayne Craig,Clare Tibke,Rebecca Jeffery,Mohammed Paracha,Tarek Saba,Gemma Swarbrick,Judith Saba,Aashish Vyas,Janet Mills,Sarah Goddard,Anthony De Soyza,Therese Small,Ashley Dodds,Umesh Dashora,Rachael Golton
DOI: https://doi.org/10.1136/thoraxjnl-2015-208035
Thorax
Abstract:Background: Severe exacerbations of COPD are commonly associated with hyperglycaemia, which predicts adverse outcomes. Metformin is a well-established anti-hyperglycaemic agent in diabetes mellitus, possibly augmented with anti-inflammatory effects, but its effects in COPD are unknown. We investigated accelerated metformin therapy in severe COPD exacerbations, primarily to confirm or refute an anti-hyperglycaemic effect, and secondarily to explore its effects on inflammation and clinical outcome. Methods: This was a multicentre, randomised, double-blind, placebo-controlled trial testing accelerated metformin therapy in non-diabetic patients, aged ≥35 years, hospitalised for COPD exacerbations. Participants were assigned in a 2:1 ratio to 1 month of metformin therapy, escalated rapidly to 2 g/day, or matched placebo. The primary end point was mean in-hospital blood glucose concentration. Secondary end points included the concentrations of fructosamine and C reactive protein (CRP), and scores on the COPD Assessment Test and Exacerbations of Chronic Pulmonary Disease Tool. Results: 52 participants (mean (±SD) age 67±9 years) were randomised (34 to metformin, 18 to placebo). All were included in the primary end point analysis. The mean blood glucose concentrations in the metformin and placebo groups were 7.1±0.9 and 8.0±3.3 mmol/L, respectively (difference -0.9 mmol/L, 95% CI -2.1 to +0.3; p=0.273). No significant between-group differences were observed on any of the secondary end points. Adverse reactions, particularly gastrointestinal effects, were more common in metformin-treated participants. Conclusion: Metformin did not ameliorate elevations in blood glucose concentration among non-diabetic patients admitted to hospital for COPD exacerbations, and had no detectable effect on CRP or clinical outcomes. Trial registration number: ISRCTN66148745 and NCT01247870.